Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (âMonoparâ or the âCompanyâ) (Nasdaq: MNPR), a clinicalâstage biopharmaceutical company focused on developing innovativ...
How might macroâeconomic factors (e.g., interest rates, biotech funding environment) impact Monopar's ability to raise additional capital if needed?
What is the market's perception of the recent developmentsâare analysts upgrading/downgrading the stock, and what are the new target price revisions?
Did the company disclose any changes in its capital structure, such as new debt facilities, equity offerings, or share buyback programs?
24 days ago